More strikingly, combination of EpCAM/CD3 BsAb and MUC-1/CD3 BsAb effectively improved the immune microenvironment by increasing CD8+ T cells but decreasing Tregs in TDLNs, thereby led to potent antitumor responses, suggesting its potential advantage for the therapy of targeting EpCAM and MUC-1 on tumor. This evidence concerns the gene CD8A and neoplasm.